Drug intelligence / Profile preview

modakafusp alfa + pembrolizumab

Development stage: Unknown
Lead developer: Takeda
Modality: Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

modakafusp alfa + pembrolizumab is an investigational combination therapy being evaluated primarily for metastatic or unresectable cutaneous melanoma. Modakafusp alfa (TAK-573) is a first-in-class immunocytokine that fuses two interferon-alpha2b variants to an anti-CD38 IgG4 monoclonal antibody, designed to deliver interferon signaling selectively to CD38-expressing cells. Pembrolizumab is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor monoclonal antibody. The combination aims to synergize immune stimulation with immune checkpoint blockade for enhanced antitumor activity in resistant melanoma[1][3][4].

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on modakafusp alfa + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on modakafusp alfa + pembrolizumab.

Explore the full profile